Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Oct 15 '24 | Option Exercise | 1.85 | 5,408 | 10,005 | 76,773 | Oct 17 05:09 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Oct 15 '24 | Sale | 7.41 | 5,408 | 40,073 | 71,365 | Oct 17 05:09 PM | Yednock Ted | Officer | Oct 15 '24 | Proposed Sale | 7.41 | 5,408 | 40,073 | | Oct 15 02:03 PM | Carson William H. | Director | Oct 01 '24 | Buy | 5.97 | 3,200 | 19,104 | 22,400 | Oct 02 04:15 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sep 19 '24 | Sale | 7.10 | 4,500 | 31,950 | 0 | Sep 20 04:30 PM | Yednock Ted | Officer | Sep 19 '24 | Proposed Sale | 7.10 | 4,500 | 31,950 | | Sep 19 12:32 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sep 12 '24 | Sale | 6.16 | 5,500 | 33,880 | 4,500 | Sep 16 04:30 PM | Yednock Ted | Officer | Sep 12 '24 | Proposed Sale | 6.16 | 5,500 | 33,880 | | Sep 12 10:24 AM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sep 05 '24 | Sale | 5.64 | 5,500 | 31,020 | 10,000 | Sep 06 04:30 PM | Yednock Ted | Officer | Sep 05 '24 | Proposed Sale | 5.64 | 5,500 | 31,020 | | Sep 05 10:15 AM | Carson William H. | Director | Sep 03 '24 | Buy | 5.48 | 3,200 | 17,536 | 19,200 | Sep 04 04:34 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Aug 29 '24 | Sale | 5.95 | 5,500 | 32,725 | 15,500 | Aug 30 06:00 PM | Yednock Ted | Officer | Aug 29 '24 | Proposed Sale | 5.95 | 5,500 | 32,725 | | Aug 29 02:08 PM | Carson William H. | Director | Aug 01 '24 | Buy | 6.24 | 3,200 | 19,968 | 16,000 | Aug 05 07:53 PM | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Jul 15 '24 | Sale | 6.02 | 784 | 4,720 | 94,622 | Jul 17 04:49 PM | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Jul 15 '24 | Sale | 6.03 | 1,104 | 6,657 | 86,468 | Jul 17 04:48 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Jul 15 '24 | Sale | 6.02 | 1,106 | 6,658 | 71,365 | Jul 17 04:46 PM | Carson William H. | Director | Jul 01 '24 | Buy | 5.00 | 3,200 | 16,000 | 12,800 | Jul 02 05:43 PM | Carson William H. | Director | Jun 03 '24 | Buy | 4.83 | 3,200 | 15,459 | 9,600 | Jun 05 04:23 PM | Carson William H. | Director | May 01 '24 | Buy | 4.68 | 3,200 | 14,982 | 6,400 | May 03 04:15 PM | Carson William H. | Director | Apr 08 '24 | Buy | 6.07 | 3,200 | 19,411 | 3,200 | Apr 10 07:17 PM | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Feb 20 '24 | Sale | 5.53 | 2,593 | 14,339 | 82,058 | Feb 21 04:31 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Feb 20 '24 | Sale | 5.51 | 2,604 | 14,348 | 72,471 | Feb 21 04:31 PM | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Feb 20 '24 | Sale | 5.48 | 1,951 | 10,691 | 85,641 | Feb 21 04:31 PM | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Feb 12 '24 | Sale | 5.53 | 1,349 | 7,460 | 48,592 | Feb 14 07:59 PM | Love Douglas | PRESIDENT AND CEO | Feb 12 '24 | Sale | 5.54 | 5,782 | 32,032 | 196,121 | Feb 14 07:56 PM | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Feb 12 '24 | Sale | 5.54 | 1,809 | 10,022 | 45,651 | Feb 14 07:54 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Feb 12 '24 | Sale | 5.54 | 1,810 | 10,027 | 36,075 | Feb 14 07:52 PM | Yednock Ted | EVP & Chief Innovation Officer | Dec 27 '23 | Option Exercise | 1.63 | 21,000 | 34,176 | 21,000 | Dec 29 04:12 PM | Yednock Ted | EVP & Chief Innovation Officer | Dec 27 '23 | Sale | 4.52 | 21,000 | 94,966 | 0 | Dec 29 04:12 PM | Satter Muneer A | Director | Dec 26 '23 | Buy | 2.88 | 350,000 | 1,008,000 | 7,406,024 | Dec 28 04:30 PM |
|